Cargando…

Improved Diabetes Control and Pancreatic Function in a Type 2 Diabetic after Omeprazole Administration

A 43-year-old man with type 2 diabetes, opposed to insulin use and poorly responsive to oral agents added sequentially over 6 years, was placed on 40 mg omeprazole twice daily. A linear decline in daily fasting blood glucose was observed over the first two-month treatment, and his hemoglobin A1c was...

Descripción completa

Detalles Bibliográficos
Autores principales: Mefford, I. N., Mefford, J. T., Burris, C. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420592/
https://www.ncbi.nlm.nih.gov/pubmed/22937295
http://dx.doi.org/10.1155/2012/468609
_version_ 1782240879490105344
author Mefford, I. N.
Mefford, J. T.
Burris, C. A.
author_facet Mefford, I. N.
Mefford, J. T.
Burris, C. A.
author_sort Mefford, I. N.
collection PubMed
description A 43-year-old man with type 2 diabetes, opposed to insulin use and poorly responsive to oral agents added sequentially over 6 years, was placed on 40 mg omeprazole twice daily. A linear decline in daily fasting blood glucose was observed over the first two-month treatment, and his hemoglobin A1c was reduced from 11.9% to 8.2%, then sustained at 8.1% after four months. Glucose, insulin, and C-peptide response to a 2-hour glucose tolerance test were consistently improved across this time period, and calculated beta-cell mass increased by 67%. We believe these responses are consistent with activation or neogenesis of pancreatic beta cells, possibly through a gastrin-mediated mechanism.
format Online
Article
Text
id pubmed-3420592
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34205922012-08-30 Improved Diabetes Control and Pancreatic Function in a Type 2 Diabetic after Omeprazole Administration Mefford, I. N. Mefford, J. T. Burris, C. A. Case Rep Endocrinol Case Report A 43-year-old man with type 2 diabetes, opposed to insulin use and poorly responsive to oral agents added sequentially over 6 years, was placed on 40 mg omeprazole twice daily. A linear decline in daily fasting blood glucose was observed over the first two-month treatment, and his hemoglobin A1c was reduced from 11.9% to 8.2%, then sustained at 8.1% after four months. Glucose, insulin, and C-peptide response to a 2-hour glucose tolerance test were consistently improved across this time period, and calculated beta-cell mass increased by 67%. We believe these responses are consistent with activation or neogenesis of pancreatic beta cells, possibly through a gastrin-mediated mechanism. Hindawi Publishing Corporation 2012 2012-03-14 /pmc/articles/PMC3420592/ /pubmed/22937295 http://dx.doi.org/10.1155/2012/468609 Text en Copyright © 2012 I. N. Mefford et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Mefford, I. N.
Mefford, J. T.
Burris, C. A.
Improved Diabetes Control and Pancreatic Function in a Type 2 Diabetic after Omeprazole Administration
title Improved Diabetes Control and Pancreatic Function in a Type 2 Diabetic after Omeprazole Administration
title_full Improved Diabetes Control and Pancreatic Function in a Type 2 Diabetic after Omeprazole Administration
title_fullStr Improved Diabetes Control and Pancreatic Function in a Type 2 Diabetic after Omeprazole Administration
title_full_unstemmed Improved Diabetes Control and Pancreatic Function in a Type 2 Diabetic after Omeprazole Administration
title_short Improved Diabetes Control and Pancreatic Function in a Type 2 Diabetic after Omeprazole Administration
title_sort improved diabetes control and pancreatic function in a type 2 diabetic after omeprazole administration
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420592/
https://www.ncbi.nlm.nih.gov/pubmed/22937295
http://dx.doi.org/10.1155/2012/468609
work_keys_str_mv AT meffordin improveddiabetescontrolandpancreaticfunctioninatype2diabeticafteromeprazoleadministration
AT meffordjt improveddiabetescontrolandpancreaticfunctioninatype2diabeticafteromeprazoleadministration
AT burrisca improveddiabetescontrolandpancreaticfunctioninatype2diabeticafteromeprazoleadministration